14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ARES vs CRBG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Corebridge Financial, Inc. (CRBG) is the stronger overall head-to-head candidate over Ares Management Corporation (ARES) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARES carries a Unified Composite Score of 51.5/100 (HOLD) at $130.19 (18.7x Forward P/E, 7.2% operating margin), whereas CRBG carries 51.7/100 (HOLD) at $35.71 (6.3x Forward P/E, 20.8% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARES vs CRBG. Trailing 12-month operating profitability (ARES 7.2% vs CRBG 20.8%) and valuation multiples (ARES 18.7x vs CRBG 6.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Asset Management value chain with $15.9B market capitalization and 20.8% operating margin.
OpEx & R&D Reinvestment10.1% of Rev ($2.07B)
90D Engineering Disclosures0 Published
Investor FAQ ARES vs CRBG Key Questions & Quantitative Answers
As of Nov 16, 2026, Corebridge Financial, Inc. (CRBG) is the stronger overall head-to-head candidate over Ares Management Corporation (ARES) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARES carries a Unified Composite Score of 51.5/100 (HOLD) at $130.19 (18.7x Forward P/E, 7.2% operating margin), whereas CRBG carries 51.7/100 (HOLD) at $35.71 (6.3x Forward P/E, 20.8% operating margin). Technically, ARES sits in a Neutral phase (RSI 50.8, CONSOLIDATION options structure) and CRBG sits in a Markup phase (RSI 52.1, UNCLASSIFIED options structure).
CRBG leads the Growth & Scale pillar: ARES posts -18.7% YoY revenue growth and -81.9% YoY earnings growth on $4.98B TTM revenue (100.0% gross margin, 7.2% operating margin), compared with CRBG at +18.6% YoY revenue growth and N/A YoY earnings growth on $20.5B TTM revenue (30.9% gross margin, 20.8% operating margin). On trailing 12-month operating scale, ARES generates $4.98B in USD-normalized revenue versus $20.5B for CRBG. In operating R&D and SG&A reinvestment, ARES deploys N/A (0 90-day corporate R&D disclosures) versus 10.1% of Rev ($2.07B) (0 disclosures) for CRBG.
CRBG screens cheaper on headline valuation multiples. ARES trades at 18.7x Forward P/E, 110.3x Trailing P/E, 1.00x PEG, and 11.6x EV/Revenue (-12.3% FCF margin), whereas CRBG trades at 6.3x Forward P/E, 8.2x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (24.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARES (11.1% ROE) versus CRBG (20.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ARES carries 51.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 3.36x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.33β · 44% Vol realized risk). By comparison, CRBG carries 30.7% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.15β · 35% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.